Unlike the unified US system, running a multi-country clinical trial in Europe is a bureaucratic nightmare. A single trial can require three slightly different protocols for Switzerland, the UK, and Spain, for example, creating significant delays, costs, and complexity for investigators.

There's a growing recognition that European governments can no longer just be regulators; they must actively compete for biotech investment and clinical trials. This requires treating their country's R&D environment as a product with an "attractive offering" to win against global competitors.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

In a striking reversal from 2024, large European pharmaceutical companies secured 13 FDA approvals while their eight largest US counterparts received only four. No single US company had more than one new drug approval, highlighting a significant performance gap and a potential shift in R&D pipeline productivity between the two regions.

For a smaller company, conducting a clinical trial within one country like the UK is highly efficient. It streamlines regulation under one agency (the MHRA), reduces costs, and allows for rapid patient enrollment by leveraging a tight-knit national network of clinical specialists.

China's ability to accelerate biotech development stems from faster patient recruitment for clinical trials. With a large, treatment-naive patient population willing to participate in studies, early-stage oncology trials can be completed in about half the time it takes in the US. This provides a significant strategic advantage for de-risking assets more quickly and cheaply.

To de-risk clinical programs from recruitment and activation hurdles within the UK's strained NHS, companies like Resolution Therapeutics run an equal number of trial sites in other countries, like Spain. This geographic diversification provides a valuable real-time benchmark and a hedge against single-country operational delays.

Barcelona is an emerging biotech hub due to a specific formula: 1) excellent basic research institutions, 2) top-tier hospitals for clinical trials, 3) an active local early-stage VC community, and 4) a regional culture of entrepreneurship. This combination creates a fertile ground for new ventures to form and thrive.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.